其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Woollins' Reagent CAS Registry Number: 122039-27-4 2,4-二苯基-1,3,2,4-二硒二膦 2,4-二硒化物

CAS Name: 2,4-Diphenyl-1,3,2,4-diselenadiphosphetane 2,4-diselenide
Percent Composition: C 27.09%, H 1.89%, P 11.64%, Se 59.37%
Literature References: Selenium analog of Lawesson's reagent, q.v. Prepn: J. C. Fitzmaurice et al., J. Chem. Soc. Chem. Commun. 1988, 741; P. T. Wood, J. D. Woollins, ibid. 1190; M. J. Pilkington et al., Heteroatom Chem. 1, 351 (1990). Synthesis and characterization by 31P and 77Se NMR: G. Grossmann et al., Z. Anorg. Allg. Chem. 627, 1269 (2001). Improved synthesis: I. P. Gray et al., Chem. Eur. J. 11, 6221 (2005). X-ray crystal structure: P. Bhattacharyya et al., J. Chem. Soc. Dalton Trans. 2001, 300. Synthetic applications: I. Baxter et al., Chem. Commun. 1997, 2049; P. Bhattacharyya, J. D. Woollins, Tetrahedron Lett. 42, 5949 (2001); idem et al., Chem. Eur. J. 8, 2705 (2002); J. Bethke et al., Tetrahedron Lett. 44, 6911 (2003).

Selenomethionine CAS Registry Number: 1464-42-2 DL-硒代蛋氨酸

CAS Name: 2-Amino-4-(methylseleno)butanoic acid
Additional Names: a-amino-g-(methylseleno)butyric acid
Percent Composition: C 30.62%, H 5.65%, N 7.14%, O 16.32%, Se 40.26%
Literature References: Selenium analog of methionine. Prepn of DL-form: E. P. Painter, J. Am. Chem. Soc. 69, 232 (1949); H. J. Klosterman, E. P. Painter, ibid. 2009; G. Zdansky, Ark. Kemi 19, 559 (1962), C.A. 58, 6919h (1963). Prepn of L-form: idem, ibid. 29, 437 (1968); C. S. Pande et al., J. Org. Chem. 35, 1440 (1970). Biosynthesis of radioactive (75Se) form: M. Blau, Biochim. Biophys. Acta 49, 389 (1961). Metabolism: M. Blau, J. F. Holland in Radioactive Pharmaceuticals, G. A. Andrews et al., Eds. (USAEC Symposium Series #6, 1976) pp 409-421. Review of use in pancreatic scanning: J. E. Agnew et al., Br. J. Radiol. 49, 979-995 (1976).

Lorajmine CAS Registry Number: 47562-08-3 劳拉义明

CAS Name: (17R,21a)-Ajmalan-17,21-diol 17-(chloroacetate)
Additional Names: 17-monochloroacetylajmaline; 17-chloroacetylajmaline; MCAA
Percent Composition: C 65.58%, H 6.75%, Cl 8.80%, N 6.9...
Literature References: Semi-synthetic ajmaline derivative. Prepn from ajmaline: BE 622395 (1962 to Inverni Della Beffa), C.A. 59, 8816d (1963); A. Bonati, A. Bocchia, Farmaco Ed. Sci. 18, 84 (1963). Improved prepn: A. Bonati, DE 2023949; eidem, US 3741972 (1970, 1973 both to Inverni Della Beffa). In vitro and in vivo anti-arrhythmic activity: C. Capra, Farmaco Ed. Sci. 19, 865 (1964); cardiac action: Y. Katano et al., Arzneim.-Forsch. 23, 483 (1973); cardiovascular effects and toxicity: C. Capra et al., Farmaco Ed. Prat. 35, 49 (1980). Determination in plasma by TLC fluorescence: L. J. Dombrowski et al., J. Pharm. Sci. 64, 643 (1975). GC-MS determination in blood: St. D. Clemans et al., Arzneim.-Forsch. 27, 1128 (1977). Comparison with other ajmaline esters: M. Salmona et al., J. Pharm. Sci. 64, 1561 (1975); P. Jaillon et al., Arch. Int. Pharmacodyn. 224, 310 (1976). Clinical studies: M. Cafiero et al., Minerva Cardioangiol. 32, 59 (1984). Book: G. G. Gensini, Ed., Concepts on the Mechanism and Treatment of Arrhythmias (Futura Publishing Co., Mount Kisco, N.Y., 1974) 281 pp.

Amikacin CAS Registry Number: 37517-28-5 阿米卡星

CAS Name: O-3-Amino-3-deoxy-a-D-glucopyranosyl-(1®6)-O-[6-amino-6-deoxy-a-D-glucopyranosyl-(1®4)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy-D-streptamine
Additional Names: 1-N-[L(-)-4-amin...
Literature References: Semisynthetic aminoglycoside antibiotic derived from kanamycin A. Prepn: Kawaguchi et al., J. Antibiot. 25, 695 (1972); H. Kawaguchi, T. Naito, DE 2234315; H. Kawaguchi et al., US 3781268 (both 1973 to Bristol-Myers). Biological formation from kanamycin A: L. M. Cappelletti, R. Spagnoli, J. Antibiot. 36, 328 (1983). Microbiological evaluation: Price et al., ibid. 25, 709 (1972). Pharmacokinetics: Cabana, Taggart, Antimicrob. Agents Chemother. 3, 478 (1973). In vitro studies: Yu, Washington, ibid. 4, 133 (1973); Bodey, Stewart, ibid. 186. Pharmacology in humans: Bodey et al., ibid. 5, 508 (1974). Toxicity studies: Fujisawa et al., J. Antibiot. 27, 677 (1974). Review: K. A. Kerridge in Pharmacological and Biochemical Properties of Drug Substances vol. 1, M. E. Goldberg, Ed. (Am. Pharm. Assoc., Washington, DC, 1977) pp 125-153. Comprehensive description: P. M. Monteleone et al., Anal. Profiles Drug Subs. 12, 37-71 (1983).

TNP-470 CAS Registry Number: 129298-91-5 4-羟基-alpha-((乙基氨基)甲基)-苄醇盐酸盐

CAS Name: (Chloroacetyl)carbamic acid (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester
Additional Names: O-(chloroacetylcarbamoyl)fumagi...
Literature References: Semisynthetic analog of fumagillin that inhibits angiogenesis. Prepn: S. Kishimoto, T. Fujita, EP 359036; eidem, US 5166172 (1990, 1992 both to Takeda); S. Marui et al., Chem. Pharm. Bull. 40, 96 (1992). Antiangiogenic activity: M. Kusaka et al., Biochem. Biophys. Res. Commun. 174, 1070 (1991). HPLC determn in plasma: W. D. Figg et al., J. Chromatogr. B 652, 187 (1994). Review of pharmacology: V. Castronovo, D. Belotti, Eur. J. Cancer 32A, 2520-2527 (1996). Clinical evaluation in metastatic renal carcinoma: W. M. Stadler et al., J. Clin. Oncol. 17, 2541 (1999). Clinical pharmacokinetics in Kaposi's sarcoma: J. D. Moore et al., Cancer Chemother. Pharmacol. 46, 173 (2000).

Dibekacin CAS Registry Number: 34493-98-6 地贝卡星

CAS Name: O-3-Amino-3-deoxy-a-D-glucopyranosyl-(1®6)-O-[2,6-diamino-2,3,4,6-tetradeoxy-a-D-erythro-hexopyranosyl-(1®4)]-2-deoxy-D-streptamine
Additional Names: DKB; 3',4'-dideoxykanamycin B; de...
Literature References: Semisynthetic analog of kanamycin, q.v., effective against kanamycin-resistant bacteria. Prepn: Umezawa et al., J. Antibiot. 24, 485 (1971); eidem, Bull. Chem. Soc. Jpn. 45, 3624 (1972); Umezawa et al., DE 2135191 (1972 to Microbiochem. Res. Found.). Improved synthesis: T. Yoneta et al., Bull. Chem. Soc. Jpn. 52, 1131 (1979). Antibacterial activity: A. G. Paradelis et al., Antimicrob. Agents Chemother. 14, 514 (1978). Metabolic studies: Shimizu, Jpn. J. Antibiot. 26, 522 (1973). Toxicology: Koeda et al., ibid. 221. Pharmacokinetics and acute toxicity: I. Komiya et al., J. Pharmacobio-Dyn. 4, 356 (1981). HPLC determn in serum: H. Kubo et al., Antimicrob. Agents Chemother. 28, 521 (1985). Review: P. Noone, Drugs 27, 548-578 (1984).

Trospectomycin CAS Registry Number: 88669-04-9 丙大观霉素

CAS Name: (2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-2-Butyldecahydro-4a,7,9-trihydroxy-6,8-bis(methylamino)-4H-pyrano[2,3-b][1,4]benzodioxin-4-one
Additional Names: 6'-n-propylspectinomycin
Percent ...
Literature References: Semi-synthetic analog of spectinomycin. Prepn: D. R. White, DE 3308196; idem, US 4532336 (1983, 1985 both to Upjohn); D. R. White et al., J. Antibiot. 36, 339 (1983); P. M. Herrinton et al., J. Org. Chem. 58, 678 (1993). In vitro activity: G. E. Zurenko et al., Antimicrob. Agents Chemother. 32, 216 (1988). Mode of action: E. M. Veringa et al., Int. J. Med. Microbiol. 271, 311 (1989). Pharmacokinetic and tolerance study: G. R. Peters et al., Int. J. Clin. Pharmacol. Ther. Toxicol. 28, 361 (1990). HPLC determn in plasma and serum: R. J. Simmonds et al., J. Liq. Chromatogr. 13, 1125 (1990). Clinical study in gonorrhea: T. F. Mroczkowski et al., Drugs Exp. Clin. Res. 19, 41 (1993).

Floxacillin CAS Registry Number: 5250-39-5 氟氯西林

CAS Name: (2S,5R,6R)-6-[[[3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolyl]carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Additional Names: 3-(2-chloro-...
Literature References: Semi-synthetic antibiotic active against penicillin-resistant staphylococci. Halogen-substituted derivative of oxacillin, q.v. Prepn: ZA 6304323 (1964 to Beecham); Nayler, GB 978299; idem, US 3239507 (1964, 1966 both to Beecham). Pharmacology and toxicity: R. Sutherland et al., Br. Med. J. 4, 460 (1970). Clinical studies: Harding et al., Clin. Trials J. 7, 368 (1970); Qureshi et al., ibid. 375.

Cefazolin CAS Registry Number: 25953-19-9 头孢唑林

CAS Name: (6R,7R)-3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Additional Names: 7-(1-(1H)-tetr...
Literature References: Semi-synthetic antibiotic derived from 7-aminocephalosporanic acid, q.v. Prepn: T. Takano et al., ZA 6804513; eidem, US 3516997 (1969, 1970 to Fujisawa). Synthesis and properties: Kariyone et al., J. Antibiot. 23, 131 (1970). Activity and clinical studies: Nishida et al., ibid. 137, 184; Shibata, Fujii, Antimicrob. Agents Chemother. 1970, 467. Metabolic studies: Kozatani et al., Chem. Pharm. Bull. 20, 1105 (1972). Toxicology: H. A. Birkhead et al., J. Infect. Dis. 128, Suppl., 379 (1973). Comprehensive description: A. E. Zappala et al., Anal. Profiles Drug Subs. 4, 1-20 (1975). Review: H. Nakano in Pharmacological and Biochemical Properties of Drug Substances vol. 1, M. E. Goldberg, Ed. (Am. Pharm. Assoc., Washington, DC, 1977) pp 155-182.

Cefmetazole CAS Registry Number: 56796-20-4 头孢美唑

CAS Name: (6R,7S)-7-[[[(Cyanomethyl)thio]acetyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acidPercent Composition: C 38.21...
Literature References: Semi-synthetic antibiotic derived from cephamycin C, q.v. Prepn: H. Nakao et al., DE 2455884 (1975 to Sankyo), C.A. 83, 97330g (1975); eidem, J. Antibiot. 29, 554 (1976). See also: J. E. Dolfini, US 3920639 (1975 to Squibb). In vitro study: J. V. Uri et al., ibid. 31, 82 (1978). Immunological study: M. Iwata, T. Matuhasi, Jpn. J. Exp. Med. 48, 401 (1978). Absorption, distribution, excretion, metabolism in various species: H. Shindo et al., Chemotherapy (Tokyo) 27, Suppl. 1, 64 (1979). Pharmacology: S. Kobayashi et al., ibid. 26, Suppl. 5, 115 (1978). Toxicological studies: H. Masuda et al., Sankyo Kenkyusho Nempo 30, 112 (1978), C.A. 90, 180268h (1979). Comparative clinical study: M. Nishida et al., J. Antibiot. 32, 1319 (1979).